How much does ipilimumab cost?

Bristol-Myers Squibb is pricing ipilimumab at $30,000 per injection. This translates to a cost of $120,000 for a course of therapy, based on the approved dosing regimen of 3 mg/kg every 3 weeks for four doses. The company’s patient-assistance program, however, may reduce net pricing to $80,000.

How effective is ipilimumab and nivolumab?

The OS rate at 3 years was 58% in the nivolumab-plus-ipilimumab group and 52% in the nivolumab group, as compared with 34% in the ipilimumab group. Intracranial responses were achieved by 20% of patients in cohort 1 and 46% of patients in cohort 2.

What are the side effects of nivolumab and ipilimumab?

a reaction during the infusion – you might get a rash, shortness of breath, redness or swelling of the face and dizziness – tell your team straight away. numbness, tingling in the hands and feet or loss of feeling, or muscle spasms and weakness – call your advice line straight away if you have any of these symptoms.

Why can ipilimumab and nivolumab be used together?

This combination therapy of antibodies helps build up your immune system, which has an immunological “memory.” That means that nivolumab and ipilimumab may help your immune system continue to attack melanoma cells even after treatment.

Is ipilimumab cost effective?

3.12 Probabilistic sensitivity analysis reported a 14% chance of ipilimumab being cost effective compared with best supportive care at £50,000 per QALY gained. Deterministic sensitivity analyses showed that the ICER was sensitive to the utility values assumed for the progressive disease health state.

How much does one treatment of immunotherapy cost?

Immunotherapy is expensive. “We’re talking about treatments that cost over $100,000 per year,” said Chan. “Combine drugs and it’s over $200,000 per year.” Chan believes when we identify who will benefit and who won’t, it will make a big difference in cost for patients and in overall healthcare costs.

How often is ipilimumab given?

Ipilimumab is now approved worldwide and is one of the most common drugs used as front-line treatment for metastatic melanoma. The approved dose and schedule for ipilimumab is 3 mg/kg infused over 90 minutes administered every 3 weeks for up to four doses.

How long does it take for ipilimumab to work?

Patients receive ipilimumab intravenously (into a blood vein). Each dose takes about 90 minutes to complete. Patients receive ipilimumab on an outpatient basis without the need for a hospital stay. For metastatic melanoma, patients receive ipilimumab in doses of 3 mg/kg every 3 weeks for up to 4 doses.

What is ipilimumab made from?

Ipilimumab is made using recombinant techniques in Chinese hamster ovarian cell cultures.

How much does nivolumab cost per month?

Their analysis estimated an average sale price of $44,919.60 per month per patient for ipilimumab (3 mg/kg every 3 weeks); $12,498.76 per month per patient for nivolumab (3 mg/kg every 2 weeks); $47,697.10 per month per patient for nivolumab/ipilimumab (1 mg/kg every 3 weeks of nivolumab plus 3 mg/kg every 3 weeks of …

How much does ipilimumab cost UK?

Ipilimumab is available at a list price of £3,750 per 10-ml (50-mg) vial and £15,000 per 40-ml (200-mg) vial (excluding VAT; British national formulary [BNF], accessed online April 2016). Costs for nivolumab may vary in different settings because of negotiated procurement discounts.

How many patients have been treated with ipilimumab?

Between Feb 29, and July 9, 2012, 727 patients were enrolled and randomly assigned to ipilimumab 10 mg/kg (365 patients; 364 treated) or ipilimumab 3 mg/kg (362 patients; all treated). Median follow-up was 14·5 months (IQR 4·6–42·3) for the ipilimumab 10 mg/kg group and 11·2 months (4·9–29·4) for the ipilimumab 3 mg/kg group.

How big is the systemic clearance for ipilimumab?

Ipilimumab has a clearance of 15.3 mL/hr. 3 Systemic clearance increases proportionally with body weight. 6 With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

What is the mechanism of action of ipilimumab?

Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). 5 Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. 1,2,5 Ipilimumab was developed by Bristol-Myers Squibb and Medarex. 5

When was ipilimumab approved for Stage 3 melanoma?

It was later approved by the US FDA on October 28, 2015 for stage 3 patients as adjuvant therapy. On February 1, 2012, Health Canada approved ipilimumab for “treatment of unresectable or metastatic melanoma in patients who have failed or do not tolerate other systemic therapy for advanced disease.”